GHRP-6 vs GHRP-2

GHRP-6 and GHRP-2 are both synthetic hexapeptides studied for their ability to stimulate growth hormone (GH) secretion through activation of the ghrelin receptor (GHS-R1a). Despite this shared mechanism, they exhibit distinct pharmacological profiles that influence their research applications. GHRP-6 is one of the earliest GH secretagogues developed and is noted for pronounced appetite stimulation and emerging cytoprotective properties. GHRP-2 (pralmorelin) is more potent on a molar basis, with a cleaner safety profile in clinical trials and regulatory approval in Japan as a diagnostic agent for GH deficiency. These differences affect dosing protocols, side effect profiles, and suitability for specific research contexts.

GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide that acts as a potent GH secretagogue by binding to the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. It stimulates pulsatile GH release while preserving physiological feedback mechanisms, including somatostatin inhibition. As one of the earliest GH-releasing peptides developed, it has been extensively studied in preclinical models. A distinguishing feature is its strong appetite-stimulating effect, mediated through ghrelin receptor activation in the hypothalamus. Beyond endocrine effects, GHRP-6 exhibits cytoprotective properties via the CD36 receptor, with preclinical data suggesting cardioprotective, neuroprotective, and anti-fibrotic actions. Research indicates these tissue-protective effects may be independent of GH release, offering a unique research angle. However, the evidence base for these non-endocrine effects is primarily from animal studies, with limited human data.

GHRP-2 (pralmorelin) is a synthetic hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, MW ~817.97 g/mol) that stimulates potent, dose-dependent GH release via the ghrelin receptor (GHS-R). It is considered more potent than GHRP-6, with approximately 2-3 times the GH-releasing efficacy on a molar basis, and induces less pronounced appetite stimulation. A key advantage is its clinical validation: GHRP-2 is approved in Japan as a diagnostic agent for GH deficiency (pralmorelin) and has been used therapeutically in GH-deficient children for 8-24 months, demonstrating maintained efficacy on growth velocity. Clinical studies report a placebo-like safety profile at therapeutic doses, with no significant adverse effects on glucose metabolism or adrenal function. This regulatory approval and long-term safety data provide a stronger evidence base compared to GHRP-6, which lacks similar clinical milestones.

Both GHRP-6 and GHRP-2 are studied for their effects on body composition, including potential modulation of lean body mass and fat metabolism through GH release. However, their distinct profiles lead to different research emphases. GHRP-6's appetite-stimulating properties make it relevant for studies on cachexia, muscle wasting, and weight gain, while its cytoprotective effects are investigated in models of cardiac ischemia, neurodegeneration, and fibrosis. GHRP-2, with its higher potency and cleaner safety profile, is more commonly used in research requiring precise GH elevation without confounding appetite changes or cortisol elevation. Its clinical approval for GH deficiency diagnosis also makes it a reference standard in comparative studies of GH secretagogues.

GHRP-6 is associated with intense hunger due to robust ghrelin receptor activation, which can be more pronounced than with other GH secretagogues. Transient mild increases in cortisol and ACTH have been reported, though these are typically not clinically significant. Water retention and bloating are also noted in some studies. GHRP-2 is well tolerated in clinical trials, with a placebo-like safety profile at therapeutic ranges. It may increase appetite but to a lesser degree than GHRP-6. Elevations in cortisol and prolactin are possible but are less marked than with GHRP-6. The clinical safety data for GHRP-2, including long-term use in children, provides a stronger safety evidence base. Researchers should consider these differences when selecting a peptide for studies where appetite modulation or hormonal side effects could confound results.